Aripiprazole is an atypical antipsychotic medication used to treat schizophrenia, bipolar disorder, major depressive disorder, and irritability associated with autism spectrum disorder [1][2]. It is available in various formulations, including oral tablets, orally disintegrating tablets, oral solution, and injectable forms [3]. The "controlled" aspect of aripiprazole typically refers to controlled-release or extended-release formulations designed to maintain stable drug levels in the body over a prolonged period, reducing the frequency of dosing [4].
What forms of aripiprazole are available?
Aripiprazole is marketed under the brand name Abilify and is also available as a generic medication [1]. It comes in several forms:
* Oral tablets: Standard immediate-release tablets for daily oral administration [3].
* Orally disintegrating tablets (ODTs): These tablets dissolve quickly in the mouth without the need for water, which can be beneficial for patients who have difficulty swallowing [3].
* Oral solution: A liquid form of the medication [3].
* Injectable formulations: Available for both intramuscular (IM) and long-acting intramuscular (IM) use [3]. The long-acting injectable (LAI) form provides sustained release over weeks or months, eliminating the need for daily oral dosing [5].
How do controlled-release aripiprazole formulations work?
Controlled-release formulations of aripiprazole are designed to release the active ingredient gradually over time. This mechanism aims to achieve consistent therapeutic drug concentrations in the bloodstream, which can lead to more stable symptom control and potentially fewer side effects associated with fluctuating drug levels [4]. Extended-release (ER) formulations, for instance, are engineered with specialized delivery systems that control the rate of drug absorption [6].
When does aripiprazole patent exclusivity expire?
Patent exclusivity for aripiprazole has largely expired, allowing for the availability of generic versions of the immediate-release formulations [7]. For specific long-acting injectable formulations, patent expiry dates may differ and can be found on specialized patent tracking websites like DrugPatentWatch.com [8].
What are the benefits of controlled-release aripiprazole?
Controlled-release aripiprazole formulations, particularly long-acting injectables, can offer significant advantages. These include improved patient adherence to treatment regimens, as the dosing schedule is less frequent compared to daily oral medication [5]. This can be particularly helpful for individuals with conditions that may impair their ability to take medication consistently [5]. Stable drug levels achieved by controlled-release mechanisms can also contribute to more consistent symptom management [4].
What are the side effects of aripiprazole?
Common side effects of aripiprazole can include nausea, vomiting, constipation, headache, dizziness, drowsiness, insomnia, and weight gain [1][2]. Less common but serious side effects may include tardive dyskinesia (involuntary muscle movements), neuroleptic malignant syndrome (NMS), and increased risk of stroke in elderly patients with dementia-related psychosis [1][2]. Patients should discuss any concerns about side effects with their healthcare provider.
How does aripiprazole compare to other antipsychotics?
Aripiprazole is an atypical antipsychotic, a class of drugs that primarily work by affecting dopamine and serotonin receptor activity in the brain [1]. Unlike some older typical antipsychotics, atypical antipsychotics generally have a lower risk of causing extrapyramidal side effects (movement disorders) but may carry a higher risk of metabolic side effects such as weight gain, diabetes, and high cholesterol [9]. Specific comparisons between aripiprazole and other medications like risperidone or olanzapine would depend on the patient's individual condition, response, and tolerability profile [9].
What are the risks of using aripiprazole in elderly patients with dementia-related psychosis?
Aripiprazole, like other atypical antipsychotics, carries an increased risk of death when used in elderly patients with dementia-related psychosis [1][2]. This risk is primarily associated with conditions such as pneumonia, heart problems, and stroke [1]. Therefore, these medications are generally not recommended for treating psychosis in this population [1].
---
Sources:
[1] https://www.nhs.uk/medicines/aripiprazole/
[2] https://www.mayoclinic.org/drugs-supplements/aripiprazole-oral-route-injection-route/side-effects/drh-20061146
[3] https://www.drugs.com/abilify.html
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921785/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179217/
[6] https://www.rxlist.com/abilify-drug.htm
[7] https://www.drugpatentwatch.com/drug/aripiprazole
[8] https://www.drugpatentwatch.com/
[9] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3854047/